

3-Dimensional Pharmaceuticals Incorporated

[View the current 3-Dimensional Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocomplete/4-3-Dimensional+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/biocomplete/4-3-Dimensional+Pharmaceuticals+Incorporated.html>)

Contact Details:

Three Lower Makefield Corporate Center 1020

Stony Hill Road

Yardley

PA

19341

United States of America

Tel: (267)-757-7200

Fax:

Email:

3-Dimensional Pharmaceuticals, Inc. (3DP) is a drug discovery company integrating advanced technologies in structure-based drug design, combinatorial chemistry and chemi-informatics. 3DP has developed an efficient and cost-effective system capable of generating new drug leads through computer-controlled robotic synthesis and analysis of chemical libraries - a patented technology known as DirectedDiversity®. 3DP is focusing its technology on the discovery and optimization of small molecule, orally acting pharmaceuticals.

Recent Publications by 3-Dimensional Pharmaceuticals Incorporated:



- [Docking: successes and challenges.](#)
The state of the art of various computational aspects of docking-based... 19th October, 2005
3-Dimensional Pharmaceuticals, Cedarbrook Corporate Center, 8 Clarke- Curr Pharm Des. 2005;11(3):323-33.
- [\[Targeted anticancer drugs and their development\]](#)
The state of the art of various computational aspects of docking-based... 11th May, 2005
3-Dimensional Pharmaceuticals, Johnson & Johnson Pharmaceutical Research- Duodecim. 2004;120(19):2323-30.
- [Synthesis and GABA receptor potency of 3-thiomethyl-4-\(hetero\)aryl-5-amino-1-phenylpyrazoles.](#)
A convenient synthetic route to novel 4-arylpyrazoles is described. The... 25th March, 2005
3-Dimensional Pharmaceuticals, Inc., A wholly owned Johnson & Johnson- Bioorg Med Chem Lett. 2004 Oct 4;14(19):4949-53. ([DOI Direct Link](#))
- [Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.](#)
Studies on integrin alphaVbeta3 have implicated this receptor in a number... 11th February, 2005
3-Dimensional Pharmaceuticals, Inc, Eagleview Corporate Center, 665- Bioorg Med Chem Lett. 2004

- Sep 6;14(17):4553-5. ([DOI Direct Link](#))
- [Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.](#)
*Through structure-based drug design and parallel synthesis, we have...*8th February, 2005
3-Dimensional Pharmaceuticals, Inc., 665 Stockton Drive, Exton, PA 19341,- Bioorg Med Chem Lett. 2004 Jul 16;14(14):3727-31. ([DOI Direct Link](#))
 - [Development of a quantitative, high-throughput cell-based enzyme-linked immunosorbent assay for detection of colony-stimulating factor-1 receptor tyrosine kinase inhibitors.](#)
*Inhibitors of receptor tyrosine kinases are implicated as therapeutic...*3rd February, 2005
Department of Discovery Biology, 3-Dimensional Pharmaceuticals Inc., 665- J Biochem Biophys Methods. 2004 Jul 30;60(1):69-79. ([DOI Direct Link](#))
 - [A novel series of potent and selective small molecule inhibitors of the complement component C1s.](#)
*Activation of the classical pathway of complement has been implicated in...*7th January, 2005
3-Dimensional Pharmaceuticals Inc, 665 Stockton Drive, Exton, PA 19341,- Bioorg Med Chem Lett. 2004 Jun 21;14(12):3043-7. ([DOI Direct Link](#))
 - [A method for quantifying and visualizing the diversity of QSAR models.](#)
*Feature selection is one of the most commonly used and reliable methods...*22nd October, 2004
3-Dimensional Pharmaceuticals, Inc., 8 Clarke Drive, Cranbury, NJ 08512,- J Mol Graph Model. 2004 Mar;22(4):275-84. ([DOI Direct Link](#))
 - [5-amino-1-\(2,6-dichloro-4-trifluoromethyl-phenyl\)-3-\[3H3\]-methylsulfanyl-1 H-pyrazole-4-carbonitrile \(CTOM\): synthesis and characterization of a novel and selective insect GABA receptor radioligand.](#)
*Pyrazole 2a is a novel, potent ligand for insect GABA receptors obtained...*9th July, 2004
3-Dimensional Pharmaceuticals, Inc., 665 Stockton Drive, Suite 104, Exton,- Bioorg Med Chem Lett. 2003 Nov 17;13(22):4035-7.
 - [Using in vitro human tissues to predict pharmacokinetic properties.](#)
*Pressure on drug discovery teams to predict the success of drug candidates...*15th June, 2004
3-Dimensional Pharmaceuticals Inc, 665 Stockton Drive, Exton, PA 19341,- Curr Opin Drug Discov Devel. 2004 Jan;7(1):69-74.
 - [Solid-phase synthesis of a library of hydroxyproline derivatives.](#)
*The synthesis of a library of N-alkylated O-arylated hydroxyproline...*4th June, 2004
3-Dimensional Pharmaceuticals, Inc., 8 Clarke Drive, Cranbury, New Jersey- J Comb Chem. 2004 Jan-Feb;6(1):91-8. ([DOI Direct Link](#))
 - [Solid-Phase Synthesis of 2,4-diaminopyrimidines via Lewis acid-mediated aromatic nucleophilic substitution.](#)
*Primary amines were immobilized on...*11th May, 2004
3-Dimensional Pharmaceuticals Inc., 8 Clarke Drive, Cranbury, New Jersey- J Comb Chem. 2004 May-Jun;6(3):414-9. ([DOI Direct Link](#))

Press Releases on 3-Dimensional Pharmaceuticals

Incorporated:

[Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference](#)

25th November, 2009 Ardea Biosciences, Inc.

SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper

[iThemba
Pharmaceuticals \(Pty\)
Ltd and Pyxis
Discovery B.V.
Announce
Collaborative
Agreement to Offer a
Combined Service
Offering](#)

25th November,
2009

*DELFT, The Netherlands and
JOHANNESBURG, November 25 /PRNewswire/
-- iThemba Pharmaceuticals & Pyxis
Discovery announced today
that they have signed a collaborative agreement*

[Reportlinker Adds
Cell/Tissue Culture
Supplies - A Global
Market Perspective](#)

25th November,
2009 Reportlinker

*NEW YORK, Nov. 25 /PRNewswire/ --
Reportlinker.com announces that a new market
research report is available in its catalogue:
Cell/Tissue Culture Supplies - A Global Market
Perspective <http://www>*

[Reportlinker Adds
Intranasal Drug
Delivery - US Market
Trends & Analysis](#)

25th November,
2009 Reportlinker

*NEW YORK, Nov. 25 /PRNewswire/ --
Reportlinker.com announces that a new market
research report is available in its catalogue:
Intranasal Drug Delivery - US Market Trends &
Analysis <http://www>*

[Reportlinker Adds
Pain Management -
Global Trends](#)

25th November,
2009 Reportlinker

*NEW YORK, Nov. 25 /PRNewswire/ --
Reportlinker.com announces that a new market
research report is available in its catalogue: Pain
Management - Global Trends
<http://www.reportlinker.com/p0164220/Pain>*

BioNews Results for 3-Dimensional Pharmaceuticals Incorporated



- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Pharma Live: Nov 5 2009 4:59PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Pharmacy Choice: Nov 4 2009 8:16AM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
CNW Group via Yahoo!: Nov 3 2009 8:55PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Canada NewsWire: Nov 3 2009 9:00PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Earthtimes.org: Nov 3 2009 9:05PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Houston Chronicle: Nov 3 2009 9:07PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Street Insider: Nov 3 2009 9:02PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
NewsBlaze: Nov 3 2009 9:02PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
PR Newswire via Yahoo!: Nov 3 2009 8:58PM Matching: 3 dimensional pharmaceuticals

- [Cipher appoints Dr. William Claypool to Board of Directors / Toronto Stock Exchange Symbol: DND](#)
FinanzNachrichten.de: Nov 3 2009 8:57PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Canoe Money: Nov 3 2009 9:57PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
PR Newswire via MSN Money: Nov 3 2009 9:02PM Matching: 3 dimensional pharmaceuticals
- [Cipher appoints Dr. William Claypool to Board of Directors](#)
Canadian Business Magazine: Nov 3 2009 9:13PM Matching: 3 dimensional pharmaceuticals

3-Dimensional Pharmaceuticals Incorporated Patents:



- 6291192- [Method for identifying conditions that facilitate recombinant protein folding](#)
- 6423948- [Microtiter plate with integral heater](#)
- 6434490- [Method of generating chemical compounds having desired properties](#)
- 6453246- [System, method, and computer program product for representing proximity data in a multi-dimensional space](#)
- 6469029- [Azacycloalkanone serine protease inhibitors](#)
- 6472399- [Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors](#)
- 6476016- [Cyclic oxyguanidine pyrazinones as protease inhibitors](#)
- 6486174- [Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists](#)
- 6492403- [Methods of treating C1s-mediated diseases and conditions and compositions thereof](#)
- 6506784- [Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides](#)
- 6514978- [Thromboresistant materials incorporating pyrazinone protease inhibitors](#)
- 6421612- [System, method and computer program product for identifying chemical compounds having desired properties](#)
- 6420397- [Heteroaryl protease inhibitors and diagnostic imaging agents](#)
- 6417161- [Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors](#)
- 6291514- [Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors](#)
- 6295514- [Method, system, and computer program product for representing similarity/dissimilarity between chemical compounds](#)
- 6303322- [Method for identifying lead compounds](#)
- 6326492- [Heterocyclic protease inhibitors](#)
- 6344466- [Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6344484- [Tyrosine alkoxyguanidines as integrin inhibitors](#)
- 6344486- [Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6350764- [Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors](#)
- 6403633- [Heteroaryl amidines, methylamidines and guanidines, and use thereof as protease inhibitors](#)
- 6409988- [Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands](#)
- 6515002- [Compounds and compositions for treating C1s-mediated diseases and conditions](#)

- 6518266- [1- Aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides](#)
- 6767722- [Analog of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137](#)
- 6872730- [Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists](#)
- 6890930- [Quinazolinones](#)
- 6900231- [Aminopyridyl-substituted phenyl acetamides as protease inhibitors](#)
- 6962942- [Azacycloalkanone serine protease inhibitors](#)
- 7060706- [Quinazolinones](#)
- 7109354- [Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions](#)
- 7138374- [Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137](#)
- 7138530- [Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions](#)
- 7429603- [C-fms kinase inhibitors](#)
- 6737404- [Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137](#)
- 6730783- [Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6706765- [Aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6518310- [Aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6521663- [Aminoguanidiny- and Alkoxyguanidiny-substituted phenyl acetamides as protease inhibitors](#)
- 6545033- [Fused 1-\(2,6-dichloro-4-trifluoromethylphenyl\)-pyrazoles, the synthesis thereof and the use thereof as pesticides](#)
- 6562840- [Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors](#)
- 6566379- [Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors](#)
- 6569631- [Microplate thermal shift assay for ligand development using 5-\(4"dimethylaminophenyl\)-2-\(4'-phenyl\)oxazole derivative fluorescent dyes](#)
- 6571227- [Method, system and computer program product for non-linear mapping of multi-dimensional data](#)
- 6586453- [Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1](#)
- 6638931- [Aminoguanidines and alkoxyguanidines as protease inhibitors](#)
- 6706021- [Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors](#)
- 7482376- [Conjugated complement cascade inhibitors](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast

service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

